{"id":1004849,"date":"2026-09-21T12:06:07","date_gmt":"2026-09-21T16:06:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/"},"modified":"2026-09-21T12:06:07","modified_gmt":"2026-09-21T16:06:07","slug":"cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/","title":{"rendered":"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc.<\/strong><\/a> (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET.<\/p>\n

A webcast of the fireside chat will be available under the Events and Presentations section of the Company\u2019s investor relations website at https:\/\/investors.cullinantherapeutics.com\/events<\/strong><\/a>.<\/p>\n

\n About Cullinan Therapeutics<\/strong>\n <\/p>\n

\n
\n Cullinan Therapeutics, Inc.<\/strong>
\n <\/a>\u00a0(Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at\u00a0https:\/\/cullinantherapeutics.com\/<\/strong><\/a>, and follow Cullinan on\u00a0LinkedIn<\/strong><\/a>\u00a0and\u00a0X<\/strong><\/a>.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Nick Smith
+1 401.241.3516
Nsmith@cullinantx.com<\/a><\/p>\n

\n Media<\/strong>
\n
Rose Weldon
+1 215.801.7644
Rweldon@cullinantx.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company\u2019s investor relations website at https:\/\/investors.cullinantherapeutics.com\/events. About Cullinan Therapeutics Cullinan Therapeutics, Inc. \u00a0(Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and … <\/p>\n

Continue reading “Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1004849","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nCullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company\u2019s investor relations website at https:\/\/investors.cullinantherapeutics.com\/events. About Cullinan Therapeutics Cullinan Therapeutics, Inc. \u00a0(Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and … Continue reading "Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-21T16:06:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum\",\"datePublished\":\"2026-09-21T16:06:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/\"},\"wordCount\":215,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/\",\"name\":\"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=\",\"datePublished\":\"2026-09-21T16:06:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/","og_locale":"en_US","og_type":"article","og_title":"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company\u2019s investor relations website at https:\/\/investors.cullinantherapeutics.com\/events. About Cullinan Therapeutics Cullinan Therapeutics, Inc. \u00a0(Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and … Continue reading \"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-21T16:06:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum","datePublished":"2026-09-21T16:06:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/"},"wordCount":215,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/","name":"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=","datePublished":"2026-09-21T16:06:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDU2NCM3ODU0MjIyIzIyMDU4NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1004849"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004849\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1004849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1004849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1004849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}